Sepsis Pipeline Summary

DelveInsight’s, “Sepsis Pipeline Insight, 2026” report provides comprehensive insights about 28+ companies and 30+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sepsis Understanding

Sepsis Overview

Sepsis is a serious and progressive medical condition triggered by the body’s dysregulated response to infection, leading to widespread inflammation and potentially life-threatening organ dysfunction. It occurs more frequently in elderly individuals, patients with cancer, and those with weakened immune systems, contributing significantly to global mortality, morbidity, healthcare burden, and costs.

Disease progression to severe sepsis or septic shock is associated with hypotension, multi-organ failure, and increased risk of death, driven by disturbances in inflammatory, immune, coagulation, and oxygen-utilization pathways. In advanced stages, sepsis can result in chronic critical illness marked by profound immune suppression and metabolic dysfunction. Common symptoms include fever or hypothermia, rapid heart rate and breathing, confusion, chills, sweating, pain, skin rash, nausea, reduced urination, dizziness, while infants may present with irritability and lethargy. 

Sepsis pathophysiology is driven by an exaggerated inflammatory response to infection, characterized by the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukins, and prostaglandins from activated neutrophils and macrophages. These mediators trigger coagulation pathways while suppressing fibrinolysis, leading to microvascular thrombosis, impaired tissue perfusion, and progressive organ dysfunction. Excessive activation of the coagulation system also results in depletion of endogenous anticoagulants, further contributing to disease severity, while genetic variations in immune, inflammatory, and coagulation-related pathways may influence susceptibility and clinical outcomes. 

Diagnosis of sepsis involves blood tests to assess organ function, coagulation abnormalities, electrolyte imbalance, oxygen levels, and evidence of infection. Additional laboratory analyses of urine, wound fluid, mucus, or respiratory secretions, along with imaging modalities such as X-rays, ultrasound, CT, and MRI scans, are used to identify the underlying source and extent of infection.

Management of sepsis requires rapid and aggressive intervention to control infection, stabilize hemodynamics, and prevent progression to organ failure and other life-threatening complications. Early administration of broad-spectrum antibiotics is a cornerstone of therapy and is typically initiated promptly to target the suspected infectious source. Intensive intravenous fluid resuscitation is also essential to restore circulating volume, improve tissue perfusion, and maintain organ function. Supportive care measures are often implemented in critical care settings to manage respiratory, cardiovascular, and metabolic dysfunction associated with severe sepsis or septic shock. In patients with persistent hypotension despite adequate fluid replacement, vasopressor agents are administered to constrict blood vessels, elevate blood pressure, and support adequate organ perfusion.

"Sepsis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Sepsis Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis.

Sepsis Emerging Drugs Analysis

This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sepsis Emerging Drugs

VBI-S: Vivacelle Bio

VBI-S is an investigational lipid-based therapy composed of micelles and liposomes, designed to restore blood pressure in septic shock patients with absolute or relative hypovolemia. The therapy is being evaluated in the Phase III VBI-S-02 trial for its ability to elevate mean arterial pressure and reduce vasopressor requirements in patients unresponsive to standard fluid resuscitation. The study also assesses improvements in organ function, oxygenation, and post-treatment survival outcomes.

Nangibotide: Inotrem

Nangibotide is a TREM-1 inhibitory peptide designed to improve survival in septic shock by restoring vascular integrity and regulating the inflammatory response. Its active component, LR12, is a synthetically produced 12-amino-acid peptide that functions as a decoy receptor, blocking the interaction between TREM-1 and its ligand. In preclinical septic shock models, Nangibotide demonstrated improved survival outcomes and normalization of inflammatory and vascular dysfunction, and it later received EMA PRIME designation in 2017 and FDA Fast Track designation in 2019 for septic shock treatment. The drug is currently in Phase II stage of its development.

ATX101: AUROBAC Therapeutics

ATX101 is a first-in-class host-targeted investigational therapy being developed by for the treatment of early septic shock. The therapy is designed to target the loss of vascular integrity, a key pathophysiological driver of septic shock, with the goal of preventing disease progression and improving patient outcomes. ATX101 is currently in Phase I clinical development and represents a novel precision medicine approach for sepsis management.

Apta-1:Aptahem AB

Apta-1 is a first-in-class RNA aptamer therapeutic being developed by Aptahem AB for the treatment of sepsis and septic shock. The therapy is designed to exert immunomodulatory, anti-inflammatory, and anticoagulant effects simultaneously, aiming to restore immune balance and reduce organ damage during severe infection. Apta-1 has demonstrated favorable safety and tolerability in Phase I studies and is being advanced as a novel multi-target approach for sepsis management.

Further product details are provided in the report……..

Sepsis Drug Therapeutic Assessment

This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as:

Major Sepsis Players in Sepsis

There are approx. 28+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. Phase III include, Vivacelle Bio.

Sepsis Clinical Trial Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Sepsis Drug Route of Administration

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Sepsis Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Sepsis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sepsis Clinical Trial Activities 

The Sepsis Pipeline report provides insights into different Sepsis Clinical Trial within Phase III, II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs. 

Sepsis Pipeline Development Activities

The Sepsis Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Sepsis Pipeline Report Insights

• Sepsis Pipeline Analysis
• Sepsis Therapeutic Assessment
• Sepsis Unmet Needs
• Impact of Sepsis Drugs

Sepsis Pipeline Report Assessment

• Sepsis Pipeline Product Profiles
• Sepsis Therapeutic Assessment
• Sepsis Pipeline Assessment
• Sepsis Inactive drugs assessment
• Sepsis Market Unmet Needs

Key Questions Answered In the Sepsis Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Sepsis drugs?
• How many Sepsis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Sepsis and their status?
• What are the key designations that have been granted to the emerging drugs?

Sepsis Key Players

• Vivacelle Bio
• Inotrem
• AUROBAC Therapeutics
• Aptahem AB
• Shanghai Yidian Pharmaceutical Technology Development
• Swedish Orphan Biovitrum AB
• SNIPR Biome
• Matisse Pharmaceuticals
• Grand Pharma
• ABIONYX Pharma
• AdrenoMed AG
• Bayer
• Artcline GmbH
• AstraZeneca
• Op-T LLC

Sepsis Key Products

• VBI-S
• Nangibotide 
• ATX101
• Apta-1
• YD0743
• Emapalumab
• SNIPR001
• M6229
• STC3141
• CER-001
• Enibarcimab
• BAY 3389934
• ARTICE
• AZD4144
• OPT101